

# ES PATENT AND TRADEMARK OFFICE

APR 26

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Sox 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPL NO.

OR 371

FIL FEE REC'D ART UNIT

ATTY.DOCKET NO

TOT CLMS **DRAWINGS** 

IND CLMS

16

10/731,737

12/09/2003

3738

0.00

VASC 1002-12

**CONFIRMATION NO. 5145** 

22470 HAYNES BEFFEL & WOLFELD LLP P O BOX 366 HALF MOON BAY, CA 94019

FILING RECEIPT

OC0000000121083941

Date Mailed: 03/16/2004

8

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

# Applicant(s)

Katherine J. Klumb, Los Altos, CA; Thomas J. Fogarty, Portola Valley, CA; Kirti P. Kamdar, Sunnvvale, CA; Bradley B. Hill, Portola Valley, CA;

#### **Assignment For Published Patent Application**

VASCULAR ARCHITECTS, INC., A Delaware corporation, San Jose, CA;

#### Domestic Priority data as claimed by applicant

This application is a CON of 09/834,145 04/12/2001 PAT 6,660,032 which is a CON of 09/400,955 09/22/1999 PAT 6,645,237 which is a CIP of 09/258,542 02/26/1999 PAT 6,248,122

HAYNES BEFFEL & WOLFELD LLP

**Foreign Applications** 

MAR 2 2 2004

If Required, Foreign Filing License Granted: 03/15/2004

RECEIVED

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No

\*\* SMALL ENTITY \*\*

Title

Expandable coil endoluminal prosthesis

**Preliminary Class** 

623

# LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

#### GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

## **NOT GRANTED**

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).



# HAYNES BEFFEL & WOLFELD LLP

P.O. Box 366, 751 Kelly Street Half Moon Bay, CA 94019 Phone 650-712-0340 Fax 650-712-0263 www.HMBay.com MARK HAYNES ERNIE BEFFEL WARREN WOLFELD

> Of Coursel: JIM HANN \*BILL KENNEDY KENTA SUZUE

\*admitted in MA only

21 April 2004

Allan W. May Chairman of the Board Vascular Architects, Inc. 1830 Bering Drive San Jose, CA 95112

Re:

U.S. Continuation Patent Application entitled

EXPANDABLE COIL ENDOLUMINAL PROSTHESIS

Application No.: 10/731,737; Filed: 9 December 2003

Inventors: Katherine J. Klumb, Thomas J. Fogarty, Kirti P. Kamdar, and Bradley B. Hill

Our Reference No.: VASC 1002-12

Dear Allan:

Enclosed is a copy of the official Filing Receipt received for the above-identified U.S. patent application. The application has been assigned **Application No. 10/731,737** and Confirmation No. **5145**, and was granted a filing date of **9 December 2003**. Also enclosed are copies of the Notice to File Missing Parts and the response that was filed with the USPTO on 31 March 2004.

## **PUBLICATION OF APPLICATION**

The application will be published as a pending application on a date to be determined pending completion of missing parts.

# NOTICE RE DUTY OF DISCLOSURE

Please note that all individuals, including inventors and attorneys, associated with the prosecution of this application have an ongoing duty to disclose to the U.S. Patent and Trademark Office all information of which they are aware which is material to the examination of the application. Information is considered material if it is not cumulative and (a) it raises a prima facie case of unpatentability of a claim or (b) it refutes or is inconsistent with any position taken by the applicant.

Material information includes information concerning the "prior art" related to the claimed invention. The "prior art" includes patents, patent applications, publications (such as books, theses, articles, advertisements and other printed materials available to some segment of the public), and products or processes similar to or related to the invention (whether yours or a competitor's).

Material information also includes the names of all inventors (and the fact of any inventorship disputes) and the earliest date of any commercial activity relating to the invention (or an earlier version

Allan May Vascular Architects, Inc. 21 April 2004

of it), such as sales, offers for sale, advertising and other sales solicitation, and public use (including secret commercial use).

In compliance with our duty of disclosure, we filed the enclosed Disclosure Statement with the Patent office on April 21, 2004, listing what we believe to be material information relating to your application. IF YOU ARE AWARE OF ANY OTHER MATERIAL INFORMATION, PLEASE LET ME KNOW. Note that any additional Information Disclosure Statements should be filed with the Patent Office within three months of the above-referenced filing date to ensure we avoid additional fees.

Failure to comply with our duty of disclosure can, at a minimum, make any patent we get on the invention unenforceable. Therefore, if you are not sure whether certain information is material, please let us decide if it should be disclosed. Naturally, if we are unaware of material information, we cannot discharge your duty to disclose that information to the U.S. Patent Office.

Please note that this duty to disclose material information continues throughout the pendency of your patent application. Therefore, if you subsequently learn of any material information, please contact us.

When I receive an office action from the patent office, I usually like to proceed as follows. Unless you have advised me otherwise, I assume you're still interested in obtaining a patent on the invention. I first review the office action and determine if I have enough information to prepare an appropriate amendment. If I do, I prepare a draft amendment, typically amending some claims and making arguments about the allowability of the claims, and send it to you with a copy of the office action. In my cover letter I typically say that I will file the amendment substantially as is unless I received contrary instructions within, for example, one month of the date of the letter. That way, if the amendment looks okay, you can either contact me asking me to file it or do nothing and I will file it in due course

Please contact me if you have any questions regarding this matter.

Yours truly,

James F. Hann

JFH:pfh Enclosures (as noted)